Article

Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)

2022-11-15

Abstract excerpt

Calreticulin (CALR) mutations are responsible for disease development in 20-30% of patients with MPNs. Mutations can be either insertions or deletions in exon 9 of CALR, both of which result in a frameshift that leads to the expression of a novel, positively charged C-terminus as well as the loss of the KDEL endoplasmic reticulum (ER)-retention signal. The mutant CALR (mutCALR) protein has a novel function that in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c0b621c2-5ffe-5c2c-88ae-22f37f2734bc
DOI: 10.1182/blood-2022-159435

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)DOI 10.1182/blood-2022-159435Read

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN.Semantic proximity Read

INCA033989: the first shot on goal for MPNs?Semantic proximity Read

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Semantic proximity Read

Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.Semantic proximity Read

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.Semantic proximity Read

Mutant calreticulin in myeloproliferative neoplasmsSemantic proximity Read

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.Semantic proximity Read

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo.Semantic proximity Read

Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative NeoplasmsSemantic proximity Read

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.Semantic proximity Read

Calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.Semantic proximity Read